Securing the Pharmaceutical Supply Chain

Excluded from normalized aggregate trends after staff review: 3056 posts were attributed to March 2026; 671 shared March 14, 2026. The preceding six-month median was 13.5 posts.

Review evidence: 3,056 posts in March 2026; 671 shared March 14, 2026; preceding six-month median 13.5. Reviewed August 9, 2026.

This company's pages remain public, but its content is excluded from normalized aggregate trends. Unfiltered raw trends and advanced filtering are available to Accelerate and Lead accounts.

Counterfeit drugs represent a significant threat to the global pharmaceutical supply chain, impacting public health and causing substantial economic damage. The complexity of the supply chain, which involves numerous stakeholders and handoffs, creates vulnerabilities that counterfeiters exploit, especially with the rise of online pharmacies and sophisticated counterfeit operations even in developed markets. Key to combating this issue are technologies like blockchain, serialization, and advanced analytics, which enhance traceability and verification. Serialization, backed by regulations such as the U.S. Drug Supply Chain Security Act, is crucial for tracking drug products from manufacture to patient, while blockchain offers a secure record of drug movements. Moreover, robust Know Your Customer (KYC) and Anti-Money Laundering (AML) practices are essential for vetting partners and preventing illicit actors from infiltrating the supply chain. Didit offers a comprehensive identity platform to address these challenges, providing tools for KYC/AML verification, document authentication, ongoing monitoring, transaction monitoring, and seamless integration with existing systems to help pharmaceutical companies mitigate risks and ensure compliance.

No tracked trend matches for this post yet.

Use this post, company, and trend context to find content marketing opportunities, perform competitive analysis, or address product feature gaps via the Plushcap MCP server or the Plushcap API.